Header Logo

Connection

Gregory Clarke to Cyclohexanols

This is a "connection" page, showing publications Gregory Clarke has written about Cyclohexanols.
Connection Strength

1.113
  1. Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression. J Am Acad Child Adolesc Psychiatry. 2013 May; 52(5):482-92.
    View in: PubMed
    Score: 0.110
  2. The bi-directional relationship between parent-child conflict and treatment outcome in treatment-resistant adolescent depression. J Am Acad Child Adolesc Psychiatry. 2013 Apr; 52(4):370-7.
    View in: PubMed
    Score: 0.110
  3. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression. J Am Acad Child Adolesc Psychiatry. 2012 Apr; 51(4):404-11.
    View in: PubMed
    Score: 0.102
  4. Out of the black box: treatment of resistant depression in adolescents and the antidepressant controversy. J Child Adolesc Psychopharmacol. 2012 Feb; 22(1):5-10.
    View in: PubMed
    Score: 0.101
  5. Treatment-resistant depressed youth show a higher response rate if treatment ends during summer school break. J Am Acad Child Adolesc Psychiatry. 2011 Nov; 50(11):1140-8.
    View in: PubMed
    Score: 0.098
  6. Pharmacokinetically and clinician-determined adherence to an antidepressant regimen and clinical outcome in the TORDIA trial. J Am Acad Child Adolesc Psychiatry. 2011 May; 50(5):490-8.
    View in: PubMed
    Score: 0.095
  7. Substance use and the treatment of resistant depression in adolescents. J Am Acad Child Adolesc Psychiatry. 2009 Dec; 48(12):1182-92.
    View in: PubMed
    Score: 0.087
  8. Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response. J Am Acad Child Adolesc Psychiatry. 2009 Mar; 48(3):330-9.
    View in: PubMed
    Score: 0.083
  9. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry. 2009 Apr; 166(4):418-26.
    View in: PubMed
    Score: 0.082
  10. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA. 2008 Feb 27; 299(8):901-13.
    View in: PubMed
    Score: 0.077
  11. The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression. J Child Adolesc Psychopharmacol. 2013 Sep; 23(7):458-67.
    View in: PubMed
    Score: 0.028
  12. Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study. J Child Adolesc Psychopharmacol. 2012 Feb; 22(1):29-36.
    View in: PubMed
    Score: 0.025
  13. Suicide attempts and nonsuicidal self-injury in the treatment of resistant depression in adolescents: findings from the TORDIA study. J Am Acad Child Adolesc Psychiatry. 2011 Aug; 50(8):772-81.
    View in: PubMed
    Score: 0.024
  14. Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample. J Clin Psychiatry. 2011 Mar; 72(3):388-96.
    View in: PubMed
    Score: 0.024
  15. Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRI-resistant depression in adolescents trial findings. Arch Gen Psychiatry. 2011 Mar; 68(3):253-62.
    View in: PubMed
    Score: 0.024
  16. Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes. Am J Psychiatry. 2010 Jul; 167(7):782-91.
    View in: PubMed
    Score: 0.022
  17. Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am J Psychiatry. 2010 Feb; 167(2):190-7.
    View in: PubMed
    Score: 0.022

© 2025 Kaiser Permanente